Corbus Pharmaceuticals (CRBP) News Today $11.92 -1.20 (-9.15%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Down 9.1% in DecemberJanuary 18 at 1:38 AM | americanbankingnews.comShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Decreases By 9.1%Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 2,410,000 shares, a drop of 9.1% from the December 15th total of 2,650,000 shares. Currently, 22.1% of the company's stock are short sold. Based on an average daily volume of 324,600 shares, the days-to-cover ratio is presently 7.4 days.January 18 at 1:38 AM | marketbeat.comBrokerages Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Target Price at $62.00January 16, 2025 | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by StockNews.com to "Sell" RatingJanuary 15, 2025 | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to Sell at StockNews.comStockNews.com upgraded Corbus Pharmaceuticals to a "sell" rating in a report on Monday.January 13, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Buy" by BrokeragesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned a consensus recommendation of "Buy" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buJanuary 13, 2025 | marketbeat.comCorbus Pharmaceuticals announes data for CRB-701 from Western Dose studyJanuary 8, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025January 8, 2025 | markets.businessinsider.comCorbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Sees Significant Growth in Short InterestCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 2,650,000 shares, an increase of 5.6% from the November 30th total of 2,510,000 shares. Currently, 24.3% of the shares of the company are short sold. Based on an average daily trading volume, of 448,900 shares, the days-to-cover ratio is currently 5.9 days.January 1, 2025 | marketbeat.comState Street Corp Buys 153,243 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)State Street Corp raised its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 34.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 595,576 shares of the biopharmaceutical company's stocDecember 26, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Buy" by BrokeragesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received a consensus recommendation of "Buy" from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has given a strDecember 19, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gainsDecember 17, 2024 | marketwatch.comCharles Schwab Investment Management Inc. Boosts Stock Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Charles Schwab Investment Management Inc. grew its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 224.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 93,643 shares of the biopharmaceutical company's stock afterDecember 17, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings Inc. stock remains steady Friday, underperforms marketDecember 14, 2024 | marketwatch.comPromising Potential of Corbus Pharmaceuticals: Buy Rating Reinforced by Key Assets and Strategic FocusDecember 12, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid TumorsDecember 9, 2024 | globenewswire.comWalleye Capital LLC Has $763,000 Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Walleye Capital LLC decreased its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 75.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,963 shares of the biopharmaceutical companyDecember 8, 2024 | marketbeat.comWhy Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 4, 2024 | msn.comHighVista Strategies LLC Grows Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)HighVista Strategies LLC raised its holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 94.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 75,292 shares of theDecember 3, 2024 | marketbeat.comFDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical CancerDecember 3, 2024 | globenewswire.comPiper Sandler Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Overweight RecommendationDecember 2, 2024 | msn.comCorbus, Viking initiated at overweight by Piper SandlerDecember 2, 2024 | msn.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Acuta Capital Partners LLCAcuta Capital Partners LLC decreased its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 71.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,500 shares of the biNovember 28, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In NowNovember 26, 2024 | insidermonkey.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Recommendation of "Buy" by BrokeragesShares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have received a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has isNovember 24, 2024 | marketbeat.comCorbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx ConferenceNovember 21, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Down 13.5% in OctoberCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 2,380,000 shares, a decline of 13.5% from the October 15th total of 2,750,000 shares. Approximately 20.2% of the shares of the company are short sold. Based on an average trading volume of 648,200 shares, the days-to-cover ratio is presently 3.7 days.November 16, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CRBP Q1 Earnings?Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Thursday, November 7th. HC Wainwright analyst A. Maldonado anticipates that the biopharmaceuticNovember 11, 2024 | marketbeat.comCorbus Pharmaceuticals (CRBP) Receives a Buy from RBC CapitalNovember 9, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors despite daily gainsNovember 9, 2024 | marketwatch.comWe're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn RateNovember 9, 2024 | finance.yahoo.comCorbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate UpdateNovember 8, 2024 | uk.finance.yahoo.comCorbus Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Reports Q3 2024 Financials and UpdatesNovember 8, 2024 | markets.businessinsider.comCorbus Pharmaceuticals presents new CRB-913 pre-clinical data at Obesity WeekNovember 5, 2024 | markets.businessinsider.comCorbus Pharmaceuticals' (CRBP) Outperform Rating Reaffirmed at WedbushWedbush reiterated an "outperform" rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday.November 4, 2024 | marketbeat.comShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Grows By 5.8%Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling 2,750,000 shares, an increase of 5.8% from the September 30th total of 2,600,000 shares. Based on an average trading volume of 638,700 shares, the days-to-cover ratio is currently 4.3 days. Currently, 23.6% of the company's stock are short sold.October 31, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Buy" from AnalystsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has been assigned an average recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating and one has assigned aOctober 30, 2024 | marketbeat.comCorbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation ConferenceOctober 29, 2024 | globenewswire.comCorbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms marketOctober 25, 2024 | marketwatch.comUp 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?October 24, 2024 | msn.comOppenheimer Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)October 22, 2024 | markets.businessinsider.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Crosses Below 50 Day Moving Average - What's Next?Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Passes Below 50 Day Moving Average - Here's WhyOctober 22, 2024 | marketbeat.comCorbus Pharmaceuticals (CRBP) Receives a Buy from Mizuho SecuritiesOctober 18, 2024 | markets.businessinsider.comCorbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)October 16, 2024 | globenewswire.comMillennium Management LLC Adjusts Stake in Corbus PharmaceuticalsOctober 16, 2024 | finance.yahoo.comShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Rises By 106.3%Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 2,600,000 shares, an increase of 106.3% from the September 15th total of 1,260,000 shares. Approximately 22.3% of the company's stock are sold short. Based on an average trading volume of 623,100 shares, the short-interest ratio is currently 4.2 days.October 11, 2024 | marketbeat.comMillennium Management LLC Has $10.94 Million Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Millennium Management LLC lessened its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 25.6% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 241,649 shares of the biopharmaceutical company's stock after sOctober 8, 2024 | marketbeat.comPoint72 Asset Management L.P. Reduces Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Point72 Asset Management L.P. lessened its holdings in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 69.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 216,515 shareOctober 1, 2024 | marketbeat.com Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBP Media Mentions By Week CRBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRBP News Sentiment▼0.670.44▲Average Medical News Sentiment CRBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRBP Articles This Week▼54▲CRBP Articles Average Week Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRGX News KURA News HUMA News OPT News MNMD News ERAS News VERV News STOK News RNAC News MGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRBP) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBP Stock Alerts